Telix Pharmaceuticals Limited (TLX)

Telix Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Feb 11, 2026	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	2,351	5,098	2,224	1,563	1,606	818
Market Cap Growth	-61.14%	129.18%	42.30%	-2.70%	96.45%	196.48%
Enterprise Value	2,580	5,038	2,144	1,482	1,572	801
Last Close Price	6.93	15.40	-	-	-	-
PE Ratio	162.52	165.02	626.21	-	-	-
PS Ratio	3.54	10.52	6.49	14.37	290.85	203.33
PB Ratio	5.57	14.50	21.91	28.75	1023.78	13.41
P/TBV Ratio	-	54.17	83.14	109.40	-	53.46
P/FCF Ratio	243.97	286.95	229.72	-	-	619.12
P/OCF Ratio	103.90	191.44	136.63	-	-	540.78
EV/Sales Ratio	3.88	10.39	6.26	13.62	284.54	199.24
EV/EBITDA Ratio	70.87	92.95	55.00	-	-	-
EV/EBIT Ratio	91.83	99.41	60.60	-	-	-
EV/FCF Ratio	267.75	283.58	221.37	-	-	606.68
Debt / Equity Ratio	0.99	1.02	0.12	0.13	1.18	0.03
Debt / EBITDA Ratio	10.42	6.47	0.30	-	-	-
Debt / FCF Ratio	43.40	20.26	1.23	-	-	1.29
Asset Turnover	0.79	0.82	1.52	0.88	0.06	0.04
Inventory Turnover	10.97	10.79	15.36	10.92	1.25	3.45
Quick Ratio	1.11	2.60	1.18	1.90	1.13	4.62
Current Ratio	1.33	2.78	1.41	2.03	1.25	4.69
Return on Equity (ROE)	3.14%	13.92%	4.55%	-253.34%	-198.36%	-60.21%
Return on Assets (ROA)	2.08%	5.33%	9.81%	-25.37%	-37.95%	-23.64%
Return on Invested Capital (ROIC)	4.44%	29.96%	599.22%	-	-	-346.56%
Return on Capital Employed (ROCE)	3.20%	6.90%	21.50%	-43.60%	-113.10%	-35.70%
Earnings Yield	0.46%	0.61%	0.16%	-4.53%	-3.64%	-4.23%
FCF Yield	0.41%	0.35%	0.43%	-3.09%	-2.75%	0.16%
Buyback Yield / Dilution	37.99%	-6.64%	-4.21%	-10.08%	-9.69%	-10.21%

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q